Table 3.

Change from baseline in PWV (LOCF), ITT population

	Placebo+MTX (n=63)	TCZ 8 mg/kg+MTX (n=69)	95% CI (p) for difference
Baseline
n	59	69
Mean (SD) PWV, m/s	9.0 (2.5)	9.0 (2.0)
Week 12
n	62	69
Mean (SD) PWV, m/s	8.4 (1.8)	8.9 (2.5)
Mean change from baseline in PWV, m/s	–0.99	–0.21	0.22 to 1.35 (p=0.0067)
Week 24
n	62	69
Mean (SD) PWV, m/s	8.9 (2.0)	9.0 (2.3)
Mean change from baseline in PWV, m/s	–0.47	–0.17	–0.27 to 0.87 (p=0.3042)

LOCF was used for missing values. Only postbaseline and pre-escape therapy scores were carried forward. All assessments were set to missing from the time of escape therapy. Mean change from baseline was adjusted for baseline age, C-reactive protein level and mean arterial pressure.

ITT, intent-to-treat; LOCF, last-observation-carried-forward; MTX, methotrexate; PWV, pulse wave velocity; TCZ, tocilizumab.